Rallybio Corporation
NASDAQ:RLYBBiotechnology
+$0.01 today
- Market cap
- $82.16M
- Beta
- -0.88
- P/E (TTM)
- -11.6
- EPS (TTM)
- -$1.37
Volume 0.03M
Average 0.25M
RLYB Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Rallybio CorporationNASDAQ: RLYB
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income declines year over year
Q1 FY2026 net income of $8.28M (cash outflow) fell 12.3% year over year, ahead of the -83.8% change in trailing-twelve-month net income. Sequentially, it rose 41.5% from the prior quarter. Over 3 fiscal years it compounded at -48.7% a year.
Context
- Net income amounted to 1046.4% of revenue in FY2025, down 8037.7 pp from a year earlier.
- Net income grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 1 analysts of -$31.07M (+246.1%) for the fiscal year ending Dec 2026, a step up from the -84.5% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$8.28M+41.5% QoQ
- Last fiscal yearDec 2025
- -$8.98M-84.5% YoY
- LTMMar 2026
- -$7.82M-83.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -12.3% | -23.5% | -11.2 pp |
| 1 year | -84.5% | +246.1% | +330.6 pp |
| 3-year CAGR | -48.7% | +25.1% | +73.8 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (8.98M) USD
- Year-over-year change
- +84.5%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (8.98M) | +84.5% |
| FY2024 | 2024-12-31 | (57.78M) | +22.5% |
| FY2023 | 2023-12-31 | (74.56M) | -11.9% |
| FY2022 | 2022-12-31 | (66.65M) | -41.8% |
| FY2021 | 2021-12-31 | (47.01M) | — |
Net Income vs competitors
How RLYB compares with its peers on the latest reported figures
- RLYB's LTM Mar 2026 net income of $7.82M is the smallest of the 4 companies compared; the peer median is $33.04M.
- Its year-over-year change of -83.8% is the lowest of 4, against a peer median of +79.8%.
- Net income amounts to 911.1% of revenue for RLYB, versus a peer median of 16552.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $55.99M | -14.8% | +8.2% | — | |
| LTM Mar 2026 | $33.24M | +155.6% | — | 61.9% | |
| LTM Jun 2026 | $33.04M | +79.8% | -20.2% | 33044.0% | |
| LTM Mar 2026 | $7.82M | -83.8% | -48.7% | 911.1% | |
| Peer median (excluding RLYB) | $33.04M | +79.8% | -6.0% | 16552.9% | |
Competitors are the stored peer set for RLYB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (47.01M) | (66.65M) | (74.56M) | (57.78M) | (8.98M) |
| Depreciation & Amortization | 109K | 167K | 150K | 131K | 92K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 3.65M | 9.5M | 10.92M | 7.99M | 5.31M |
| Change in Working Capital | (3.78M) | (936K) | 4.28M | (258K) | (4.19M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (976K) | 487K | (99K) | (698K) | (152K) |
| Other Working Capital | (2.8M) | (1.42M) | 4.38M | 440K | (4.04M) |
| Other Non-Cash Items | 1.51M | 640K | (1.05M) | 627K | (22.05M) |
| Operating Cash Flow | (45.53M) | (57.28M) | (60.27M) | (49.28M) | (29.81M) |
| Capital Expenditures | (333K) | (54K) | (12K) | 0 | 0 |
| Acquisitions (Net) | (2M) | (300K) | (2.25M) | (2M) | 0 |
| Purchases of Investments | (2M) | (201.32M) | (110.66M) | (48.93M) | (17.7M) |
| Sales of Investments | 2M | 89.5M | 138.33M | 84.43M | 46.47M |
| Other Investing Activities | (2K) | 0 | 2.25M | 0 | 18.5M |
| Investing Cash Flow | (2.33M) | (112.17M) | 27.66M | 33.49M | 47.27M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 86.2M | 51.53M | 143K | 5.41M | 16K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (3.23M) | (455K) | 0 | (206K) | 0 |
| Financing Cash Flow | 82.97M | 51.08M | 143K | 5.2M | 16K |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 35.1M | (118.38M) | (32.46M) | (10.59M) | 17.47M |
| Free Cash Flow | (45.87M) | (57.34M) | (60.28M) | (49.28M) | (29.81M) |
Rallybio Corporation
NASDAQ:RLYB
Intrinsic Alpha fair value
Locked
Current Price
$15.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.